The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer
Abstract
EGFr/HER1 and c‐erbB‐2/HER2 expression are associated with poor prognosis in breast cancer. The type I receptor tyrosine kinase (RTK) family to which they belong has four members (HER1–4). In this study, expression of HER1–4 and oestrogen receptor (ER) expression were determined by immunohistochemistry in 220 breast carcinomas. Elevated expression of HER1 was observed in 16.4%, HER2 in 22.8%, HER3 in 17.5%, and HER4 in 11.9% of these tumours. Patients whose tumours overexpressed HER1, 2 or 3 had reduced survival (p = <0.001), whereas those whose tumours overexpressed HER4 had increased survival (p = 0.013); 38.6% of cases overexpressed one or more of HER1, 2 or 3. HER4 was rarely overexpressed with other HERs (1.4% of cases). Cox's multiple regression analysis demonstrated that overexpression of HER1/2/3, HER4, and standard prognostic indicators independently affected survival. HER1–3 expression was related to ER negativity (p < 0.0001, χ 2). Patients with ER‐positive, HER1–3‐positive tumours had a significantly poorer survival (p < 0.001) than those with ER‐positive/HER‐negative or HER4‐positive tumours. Expression of HER RTKs displays complex interactions between different family members. There is a strong interaction, in terms of survival, between HER expression and ER expression. The development of HER‐targeted agents (eg Herceptin, Iressa), and agents targeted at the downstream signalling pathways, therefore provides new possibilities in the treatment of breast cancer. Copyright © 2003 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., et al. (1984) · Nature · doi:10.1038/309418a0 · Cited by 2,752
Olayioye, M. A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.13.3159 · Cited by 2,434
Coussens, L., Yang-Feng, T. L., Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, P. H., Libermann, T. A., Schlessinger, J., Francke, U., et al. (1985) · Science · doi:10.1126/science.2999974 · Cited by 1,814
Graus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590
The EGFR family and its ligands in human cancer
Yarden, Y. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00230-1 · Cited by 1,587
Phosphorylation and Regulation of Raf by Akt (Protein Kinase B)
Zimmermann, S., & Moelling, K. (1999) · Science · doi:10.1126/science.286.5445.1741 · Cited by 1,078
Ellis, M. J., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Jänicke, F., Miller, W. R., Evans, D. B., Dugan, M., Brady, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3808 · Cited by 1,060
Ross, J. S., & Fletcher, J. A. (1998) · STEM CELLS · doi:10.1002/stem.160413 · Cited by 985
Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α
Campbell, R. A., Bhat-Nakshatri, P., Patel, N. M., Constantinidou, D., Ali, S., & Nakshatri, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010840200 · Cited by 968
Ciardiello, F., Caputo, R., Bianco, R., Damiano, Pomatico, G., De Placido, S., Bianco, A. R., & Tortora, G. (2000) · PubMed · Cited by 943
Specificity within the EGF family/ErbB receptor family signaling network
Riese, D. J., & Stern, D. F. (1998) · BioEssays · doi:10.1002/(sici)1521-1878(199801)20:1<41::aid-bies7>3.0.co;2-v · Cited by 809
Baselga, J., Pfister, D., Cooper, M. R., Cohen, R., Burtness, B., Bos, M., D’Andrea, G., Seidman, A., Norton, L., Gunnett, K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.904 · Cited by 741
Kraus, M. H., Issing, W., Miki, T., Popescu, N. C., & Aaronson, S. A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.23.9193 · Cited by 737
Alroy, I., & Yarden, Y. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00412-2 · Cited by 714
Plowman, G. D., Culouscou, J. M., Whitney, G. S., Green, J. M., Carlton, G. W., Foy, L., Neubauer, M. G., & Shoyab, M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1746 · Cited by 713
Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.
Guy, P. M., Platko, J. V., Cantley, L. C., Cerione, R. A., & Carraway, K. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.17.8132 · Cited by 698 · cited 1×
“HER3 has no active kinase [23] and requires dimerization with another HER for activation [18,24].”
BackgroundPrenzel, N., Fischer, O. M., Streit, S., Hart, S., & Ullrich, A. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080011 · Cited by 673
Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.
Alimandi, M., Romano, A., Curia, M. C., Muraro, R., Fedi, P., Aaronson, S. A., Fiore, P. P. D., & Kraus, M. H. (1995) · PubMed · Cited by 548
Klapper, L. N., Glathe, S., Vaisman, N., Hynes, N. E., Andrews, G. C., Sela, M., & Yarden, Y. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.4995 · Cited by 455
Siegel, P. M. (1999) · The EMBO Journal · doi:10.1093/emboj/18.8.2149 · Cited by 442
Sun, M., Paciga, J. E., Feldman, R. I., Yuan, Z., Coppola, D., Lu, Y., Shelley, S. A., Nicosia, S. V., & Cheng, J. Q. (2001) · PubMed · Cited by 360
Rodrigues, G. A., Falasca, M., Zhang, Z., Ong, S. H., & Schlessinger, J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.4.1448-1459.2000 · Cited by 345
Role of HER2 gene overexpression in breast carcinoma
M�nard, S., Tagliabue, E., Campiglio, M., & Pupa, S. M. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200002)182:2<150::aid-jcp3>3.0.co;2-e · Cited by 303
Pianetti, S., Arsura, M., Romieu-Mourez, R., Coffey, R. J., & Sonenshein, G. E. (2001) · Oncogene · doi:10.1038/sj.onc.1204257 · Cited by 265
Receptor tyrosine kinases as targets for anticancer drugs
Zwick, E., Bange, J., & Ullrich, A. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02217-1 · Cited by 252
Evaluating HER2 amplification and overexpression in breast cancer
Bartlett, J. M. S., Going, J. J., Mallon, E. A., Watters, A. D., Reeves, J. R., Stanton, P., Richmond, J., Donald, B., Ferrier, R., & Cooke, T. G. (2001) · The Journal of Pathology · doi:10.1002/path.971 · Cited by 242
Self-citationExpression of the ERBB3 gene product in breast cancer
Lemoine, N., Barnes, D., Hollywood, D., Hughes, C., Smith, P., Dublin, E., Prigent, S., Gullick, W., & Hurst, H. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.420 · Cited by 234
Hyperactivation of MAPK Induces Loss of ERα Expression in Breast Cancer Cells
Oh, A. S., Lorant, L. A., Holloway, J. N., Miller, D. L., Kern, F. G., & El-Ashry, D. (2001) · Molecular Endocrinology · doi:10.1210/mend.15.8.0678 · Cited by 226
Expression of c-erbB3 protein in primary breast carcinomas
Naidu, R., Yadav, M., Nair, S., & Kutty, M. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.689 · Cited by 190
HER2/Neu: mechanisms of dimerization/oligomerization
Brennan, P. J., Kumogai, T., Berezov, A., Murali, R., & Greene, M. I. (2000) · Oncogene · doi:10.1038/sj.onc.1203967 · Cited by 185
Srinivasan, R., Poulsom, R., Hurst, H. C., & Gullick, W. J. (1998) · The Journal of Pathology · Cited by 183
Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer.
Dowsett, M. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080191 · Cited by 171
Pawlowski, V., Révillion-Carette, F., Hebbar, M., Hornez, L., & Peyrat, J. (2000) · PubMed · Cited by 166
Kainulainen, V., Sundvall, M., Määttä, J. A., Santiestevan, E., Klagsbrun, M., & Elenius, K. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8641 · Cited by 161
Nicholson, R. I., Hutcheson, I. R., Harper, M. E., Knowlden, J. M., Barrow, D., McClelland, R. A., Jones, H. E., Wakeling, A. E., & Gee, J. M. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080175 · Cited by 159
The ErbB receptor tyrosine family as signal integrators.
Hynes, N. E., Horsch, K., Olayioye, M. A., & Badache, A. (2001) · Endocrine Related Cancer · doi:10.1677/erc.0.0080151 · Cited by 142
Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines
DeFazio, A., Chiew, Y.-E., Sini, R. L., Janes, P. W., & Sutherland, R. L. (2000) · International Journal of Cancer · Cited by 134
Knowlden, J. M., Gee, J. M. W., Seery, L. T., Farrow, L., Gullick, W. J., Ellis, I. O., Blamey, R. W., Robertson, J. F. R., & Nicholson, R. I. (1998) · Oncogene · doi:10.1038/sj.onc.1202107 · Cited by 129
Molecular mechanism of a cross‐talk between oestrogen and growth factor signalling pathways
Kato, S., Masuhiro, Y., Watanabe, M., Kobayashi, Y., Takeyama, K., Endoh, H., & Yanagisawa, J. (2000) · Genes to Cells · doi:10.1046/j.1365-2443.2000.00354.x · Cited by 119
c-erbB-4 protein expression in human breast cancer
Kew, T. Y., Bell, J. A., Pinder, S. E., Denley, H., Srinivasan, R., Gullick, W. J., Nicholson, R. I., Blamey, R. W., & Ellis, I. O. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.1057 · Cited by 106
The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer
Gullick, W. J., & Srinivasan, R. (1998) · Breast Cancer Research and Treatment · doi:10.1023/a:1006107016969 · Cited by 103
Newman, S. P., Bates, N. P., Vernimmen, D., Parker, M. G., & Hurst, H. C. (2000) · Oncogene · doi:10.1038/sj.onc.1203416 · Cited by 100
Lee, H., Akita, R. W., Sliwkowski, M. X., & Maihle, N. J. (2001) · PubMed · Cited by 96
The Type 1 growth factor receptors and their ligands considered as a complex system.
Gullick, W. J. (2001) · Endocrine Related Cancer · doi:10.1677/erc.0.0080075 · Cited by 89
Regulation of estrogen receptor-alpha gene expression by epidermal growth factor
Stoica, A., Saceda, M., Doraiswamy, V., Coleman, C., & Martin, M. (2000) · Journal of Endocrinology · doi:10.1677/joe.0.1650371 · Cited by 81
Ram, T. G., & Ethier, S. P. (1996) · PubMed · Cited by 73
The Epidermal Growth Factor Receptor in Breast Cancer
Fox, S. B., & Harris, A. L. (1997) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1026399613946 · Cited by 63
Hyperactivation of MAPK Induces Loss of ER Expression in Breast Cancer Cells
Oh, A. S. (2001) · Molecular Endocrinology · doi:10.1210/me.15.8.1344 · Cited by 51
Vogt, U., Bielawski, K. P., Schlotter, C. M., Bosse, U., Falkiewicz, B., & Podhajska, A. J. (1998) · Gene · doi:10.1016/s0378-1119(98)00454-5 · Cited by 44
Antoniotti, S., Taverna, D., Maggiora, P., SAPEI, M. L., Hynes, N. E., & Bortoli, M. D. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.454 · Cited by 32
Cited by
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012070 · Cited by 744
A Central Role for HER3 in HER2 -Amplified Breast Cancer: Implications for Targeted Therapy
Lee-Hoeflich, S. T., Crocker, L., Yao, E., Pham, T., Munroe, X., Hoeflich, K. P., Sliwkowski, M. X., & Stern, H. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0380 · Cited by 629
Abd El‐Rehim, D. M., Ball, G., Pinder, S. E., Rakha, E., Paish, C., Robertson, J. F. R., Macmillan, D., Blamey, R. W., & Ellis, I. O. (2005) · International Journal of Cancer · doi:10.1002/ijc.21004 · Cited by 606
Schiff, R., Massarweh, S. A., Shou, J., Bharwani, L., Mohsin, S. K., & Osborne, C. K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-031212 · Cited by 462
The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer
Hsu, J. L., & Hung, M.-C. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9649-6 · Cited by 445
Metadata
- Authors
- Witton, C. J., Reeves, J. R., Going, J. J., Cooke, T. G., & Bartlett, J. M.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2003-03-31
- Volume
- 200
- Issue
- 3
- Pages
- 290-297
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W2090855460
- Cited by
- 590
- References
- 53
- FWCI
- 10.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.